Lilly’s Cyramza becomes first FDA-approved biomarker-driven therapy in patients with hepatocellular carcinoma

This article was originally published here

Concurrent with this FDA approval – the fifth for CYRAMZA – the FDA has also removed the boxed warning from the CYRAMZA labeling. HCC is the most common

The post Lilly’s Cyramza becomes first FDA-approved biomarker-driven therapy in patients with hepatocellular carcinoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply